Clinical Trials

Sutro is currently advancing two wholly owned clinical-stage programs designed to provide patient benefit across multiple areas of unmet need.

STRO-002:

REFRaME-O1

ClinicalTrials.gov Identifier: NCT05870748
A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Status: Recruiting

GM1

ClinicalTrials.gov Identifier: NCT03748186
An Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers.
STRO-002-GM1 is a novel homogeneous antibody drug conjugate using precisely positioned non-natural amino acids.
Status: Currently Not Recruiting

GM2

ClinicalTrials.gov Identifier: NCT05200364
A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
Status: Currently Not Recruiting

STRO-001:

BN301

ClinicalTrials.gov Identifier: NCT05611853
An Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Status: Not Yet Recruiting

BCM-1

ClinicalTrials.gov Identifier: NCT03424603
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies.
Received Orphan Drug designation for Multiple Myeloma patients.
Status: Closed for Enrollment

Sutro Biopharma’s investigational products have not been approved by the U.S. Food and Drug Administration or other regulatory authorities. The safety and efficacy of investigational products have not been established.